XML 40 R33.htm IDEA: XBRL DOCUMENT
v3.24.3

Collaboration and License Agreements - Additional Information (Details) - USD ($) | 1 Months Ended | 3 Months Ended | 9 Months Ended
--- | --- | --- | ---
Nov. 30, 2019 | Sep. 30, 2024 | Sep. 30, 2023 | Sep. 30, 2024 | Sep. 30, 2023
Collaboration And License Agreements [Line Items] |  |  |  |  |
Research and development |  | $ 8,287,000 | $ 14,429,000 | $ 35,091,000 | $ 39,952,000
Anacor Licensing Agreement |  |  |  |  |
Collaboration And License Agreements [Line Items] |  |  |  |  |
Number of days convenience upon written notice until first regulatory approval. | 90 days |  |  |  |
Number of days convenience upon written notice thereafter | 1 year |  |  |  |
Payment of non-refundable upfront payment | $ 2,000,000 |  |  |  |
Research and development |  | $ 0 | $ 0 | $ 0 | $ 0
Aggregate maximum payments upon achievement of development milestones | 2,000,000 |  |  |  |
Aggregate maximum payments upon achievement of commercial and sales threshold milestones | $ 125,000,000 |  |  |  |
Royalty percentage | 50.00% |  |  |  |
Number of years, sales royalty required to be paid | 15 years |  |  |  |
Brii Biosciences Agreement |  |  |  |  |
Collaboration And License Agreements [Line Items] |  |  |  |  |
Aggregate maximum payments upon achievement of commercial and sales threshold milestones | $ 150,000,000 |  |  |  |
Number of years, sales royalty required to be paid | 15 years |  |  |  |
Upfront payment received | $ 0 |  |  |  |
Brii Biosciences Agreement | Maximum |  |  |  |  |
Collaboration And License Agreements [Line Items] |  |  |  |  |
Aggregate development and regulatory milestones eligible to receive | $ 15,000,000 |  |  |  |

X
- Definition Aggregate development and regulatory milestones eligible to receive. + References No definition available. + Details
Name: | antx_AggregateDevelopmentAndRegulatoryMilestonesEligibleToReceive
Namespace Prefix: | antx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Aggregate maximum payments upon achievement of commercial and sales threshold milestones. + References No definition available. + Details
Name: | antx_AggregateMaximumPaymentsUponAchievementOfCommercialAndSalesThresholdMilestones
Namespace Prefix: | antx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Aggregate maximum payments upon achievement of development milestones. + References No definition available. + Details
Name: | antx_AggregateMaximumPaymentsUponAchievementOfDevelopmentMilestones
Namespace Prefix: | antx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaboration and license agreements. + References No definition available. + Details
Name: | antx_CollaborationAndLicenseAgreementsLineItems
Namespace Prefix: | antx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of days convenience upon written notice thereafter. + References No definition available. + Details
Name: | antx_NumberOfDaysConvenienceUponWrittenNoticeThereafter
Namespace Prefix: | antx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of days convenience upon written notice until first regulatory approval. + References No definition available. + Details
Name: | antx_NumberOfDaysConvenienceUponWrittenNoticeUntilFirstRegulatoryApproval
Namespace Prefix: | antx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of years sales royalty required to be paid. + References No definition available. + Details
Name: | antx_NumberOfYearsSalesRoyaltyRequiredToBePaid
Namespace Prefix: | antx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Payment of non-refundable upfront payment. + References No definition available. + Details
Name: | antx_PaymentOfNonRefundableUpfrontPayment
Namespace Prefix: | antx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Royalty percentage. + References No definition available. + Details
Name: | antx_RoyaltyPercentage
Namespace Prefix: | antx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront payment received. + References No definition available. + Details
Name: | antx_UpfrontPaymentReceived
Namespace Prefix: | antx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=antx_AnacorLicensingAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=antx_BriiBiosciencesAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |